812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer

812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer

Bibliographic Details
Main Authors: Hao Wang, Elizabeth Thompson, Lei Zheng, Dung Le, Christopher Wolfgang, Robert Anders, Jin He, Carol Judkins, Jessica Hoare, Rachel Klein, Rose Parkinson, Haihui Cao, Jennifer Durham, Katrina Purtell, Ana De Jesus-Acosta, Amol Narang, Richard Burkhart, William Burns, Daniel Laheru
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer
id doaj-ecf60ca4c16d4e89b7100a6bd2bc155b
record_format Article
spelling doaj-ecf60ca4c16d4e89b7100a6bd2bc155b2020-12-11T10:04:07ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0812812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancerHao Wang0Elizabeth Thompson1Lei Zheng2Dung Le3Christopher Wolfgang4Robert Anders5Jin He6Carol Judkins7Jessica Hoare8Rachel Klein9Rose Parkinson10Haihui Cao11Jennifer Durham12Katrina Purtell13Ana De Jesus-Acosta14Amol Narang15Richard Burkhart16William Burns17Daniel Laheru18Johns Hopkins University School of Medic, Baltimore, MD, USA7 Radiology Department, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia 2 Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland, USAJohns Hopkins University School of Medic, Baltimore, MD, USAAff1 0000 0001 2171 9311grid.21107.35Johns Hopkins University School of Medicine Baltimore MD USA Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USAJohns Hopkins University School of Medic, Baltimore, MD, USAJohns Hopkins University School of Medic, Baltimore, MD, USAJohns Hopkins University School of Medic, Baltimore, MD, USAJohns Hopkins University School of Medic, Baltimore, MD, USAJohns Hopkins University School of Medic, Baltimore, MD, USAJohns Hopkins University School of Medic, Baltimore, MD, USAJohns Hopkins University School of Medic, Baltimore, MD, USAJohns Hopkins University School of Medic, Baltimore, MD, USAJohns Hopkins University School of Medic, Baltimore, MD, USAJohns Hopkins University School of Medic, Baltimore, MD, USAJohns Hopkins University School of Medic, Baltimore, MD, USAJohns Hopkins University School of Medic, Baltimore, MD, USA
collection DOAJ
language English
format Article
sources DOAJ
author Hao Wang
Elizabeth Thompson
Lei Zheng
Dung Le
Christopher Wolfgang
Robert Anders
Jin He
Carol Judkins
Jessica Hoare
Rachel Klein
Rose Parkinson
Haihui Cao
Jennifer Durham
Katrina Purtell
Ana De Jesus-Acosta
Amol Narang
Richard Burkhart
William Burns
Daniel Laheru
spellingShingle Hao Wang
Elizabeth Thompson
Lei Zheng
Dung Le
Christopher Wolfgang
Robert Anders
Jin He
Carol Judkins
Jessica Hoare
Rachel Klein
Rose Parkinson
Haihui Cao
Jennifer Durham
Katrina Purtell
Ana De Jesus-Acosta
Amol Narang
Richard Burkhart
William Burns
Daniel Laheru
812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer
Journal for ImmunoTherapy of Cancer
author_facet Hao Wang
Elizabeth Thompson
Lei Zheng
Dung Le
Christopher Wolfgang
Robert Anders
Jin He
Carol Judkins
Jessica Hoare
Rachel Klein
Rose Parkinson
Haihui Cao
Jennifer Durham
Katrina Purtell
Ana De Jesus-Acosta
Amol Narang
Richard Burkhart
William Burns
Daniel Laheru
author_sort Hao Wang
title 812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer
title_short 812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer
title_full 812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer
title_fullStr 812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer
title_full_unstemmed 812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer
title_sort 812 urelumab (anti-cd137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer
publisher BMJ Publishing Group
series Journal for ImmunoTherapy of Cancer
issn 2051-1426
publishDate 2020-11-01
work_keys_str_mv AT haowang 812urelumabanticd137agonistincombinationwithvaccineandnivolumabtreatmentsissafeandassociatedwithpathologicresponseasneoadjuvantandadjuvanttherapyforresectablepancreaticcancer
AT elizabeththompson 812urelumabanticd137agonistincombinationwithvaccineandnivolumabtreatmentsissafeandassociatedwithpathologicresponseasneoadjuvantandadjuvanttherapyforresectablepancreaticcancer
AT leizheng 812urelumabanticd137agonistincombinationwithvaccineandnivolumabtreatmentsissafeandassociatedwithpathologicresponseasneoadjuvantandadjuvanttherapyforresectablepancreaticcancer
AT dungle 812urelumabanticd137agonistincombinationwithvaccineandnivolumabtreatmentsissafeandassociatedwithpathologicresponseasneoadjuvantandadjuvanttherapyforresectablepancreaticcancer
AT christopherwolfgang 812urelumabanticd137agonistincombinationwithvaccineandnivolumabtreatmentsissafeandassociatedwithpathologicresponseasneoadjuvantandadjuvanttherapyforresectablepancreaticcancer
AT robertanders 812urelumabanticd137agonistincombinationwithvaccineandnivolumabtreatmentsissafeandassociatedwithpathologicresponseasneoadjuvantandadjuvanttherapyforresectablepancreaticcancer
AT jinhe 812urelumabanticd137agonistincombinationwithvaccineandnivolumabtreatmentsissafeandassociatedwithpathologicresponseasneoadjuvantandadjuvanttherapyforresectablepancreaticcancer
AT caroljudkins 812urelumabanticd137agonistincombinationwithvaccineandnivolumabtreatmentsissafeandassociatedwithpathologicresponseasneoadjuvantandadjuvanttherapyforresectablepancreaticcancer
AT jessicahoare 812urelumabanticd137agonistincombinationwithvaccineandnivolumabtreatmentsissafeandassociatedwithpathologicresponseasneoadjuvantandadjuvanttherapyforresectablepancreaticcancer
AT rachelklein 812urelumabanticd137agonistincombinationwithvaccineandnivolumabtreatmentsissafeandassociatedwithpathologicresponseasneoadjuvantandadjuvanttherapyforresectablepancreaticcancer
AT roseparkinson 812urelumabanticd137agonistincombinationwithvaccineandnivolumabtreatmentsissafeandassociatedwithpathologicresponseasneoadjuvantandadjuvanttherapyforresectablepancreaticcancer
AT haihuicao 812urelumabanticd137agonistincombinationwithvaccineandnivolumabtreatmentsissafeandassociatedwithpathologicresponseasneoadjuvantandadjuvanttherapyforresectablepancreaticcancer
AT jenniferdurham 812urelumabanticd137agonistincombinationwithvaccineandnivolumabtreatmentsissafeandassociatedwithpathologicresponseasneoadjuvantandadjuvanttherapyforresectablepancreaticcancer
AT katrinapurtell 812urelumabanticd137agonistincombinationwithvaccineandnivolumabtreatmentsissafeandassociatedwithpathologicresponseasneoadjuvantandadjuvanttherapyforresectablepancreaticcancer
AT anadejesusacosta 812urelumabanticd137agonistincombinationwithvaccineandnivolumabtreatmentsissafeandassociatedwithpathologicresponseasneoadjuvantandadjuvanttherapyforresectablepancreaticcancer
AT amolnarang 812urelumabanticd137agonistincombinationwithvaccineandnivolumabtreatmentsissafeandassociatedwithpathologicresponseasneoadjuvantandadjuvanttherapyforresectablepancreaticcancer
AT richardburkhart 812urelumabanticd137agonistincombinationwithvaccineandnivolumabtreatmentsissafeandassociatedwithpathologicresponseasneoadjuvantandadjuvanttherapyforresectablepancreaticcancer
AT williamburns 812urelumabanticd137agonistincombinationwithvaccineandnivolumabtreatmentsissafeandassociatedwithpathologicresponseasneoadjuvantandadjuvanttherapyforresectablepancreaticcancer
AT daniellaheru 812urelumabanticd137agonistincombinationwithvaccineandnivolumabtreatmentsissafeandassociatedwithpathologicresponseasneoadjuvantandadjuvanttherapyforresectablepancreaticcancer
_version_ 1724386510672756736

Similar Items